Skip to main content

Table 1 Baseline demographics and disease characteristics

From: A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee

  Part A Part B
   AMG 108   
  Placebo ( n = 16) 100 mg IV ( n = 12) 300 mg IV ( n = 12) 300 mg SC ( n = 12) 75 mg SC ( n = 12) All AMG 108 ( n = 48) Placebo ( n = 80) AMG 108 300 mg SC ( n = 80)
Mean age (years) 60.8 61.1 62.8 59.6 62.3 61.4 60.1 61.3
Female, n (%) 10 (63) 11 (92) 7 (58) 5 (42) 9 (75) 32 (67) 54 (68) 54 (68)
Ethnicity, n (%)         
   White 15 (94) 12 (100) 12 (100) 12 (100) 12 (100) 48 (100) 66 (83) 67 (84)
   Black 1 (6) 0 0 0 0 0 2 (3) 7 (9)
   Hispanic - - - - - - 12 (15) 6 (8)
Mean weight (kg) 83.8 79.9 90.7 85.5 82.4 84.6 87.6 88.2
Mean BMI (kg/m2) 30.4 30.8 31.9 29.8 30.9 30.8 31.9 32.0
Duration of OA (years) 9.6 6.9 10.2 6.6 10.0 8.4 6.1 6.1
Kellgren-Lawrence score (n (%))         
   1 2 (13) 3 (25) 1 (8) 0 3 (25) 7 (15) 4 (5) 1 (1)
   2 4 (25) 3 (25) 7 (58) 5 (42) 4 (33) 19 (40) 30 (38) 40 (50)
   3 10 (63) 6 (50) 4 (33) 7 (58) 5 (42) 22 (46) 46 (58) 39 (49)
  1. BMI, body mass index; IV, intravenous; OA, osteoarthritis; SC, subcutaneous.